Skip to main content
PFE
NYSE Life Sciences

Pfizer Beats on Q3, Raises 2026 Revenue Guidance to $62-64B and EPS to $2.95-$3.05

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$30.625
Mkt Cap
$174.809B
52W Low
$23.62
52W High
$31.04
52W Position info
30% above low
Off High info
1.3% below high
Rel. Volume info
1.5× avg
Market data snapshot near publication time

PFE sits 30% above its 52-week low of $23.62.

Summary

Pfizer reported Q3 2026 revenue of $16.6 billion, flat year-over-year but up 7% excluding COVID products, and raised full-year revenue guidance to $62-64 billion and adjusted EPS to $2.95-$3.05. Adjusted EPS of $0.87 matched last year despite $4.3 billion of nine-month impairments.

Updates

  1. · Benzinga — Pfizer's Q3 non-COVID portfolio grew 7% operationally, with Eliquis sales up 25% to $2.52 billion and Padcev up 55% to $720 million; shares fell 1.01% to $30.36.

    • Q3 Results vs Consensus — Q3 revenue of $16.58 billion beat consensus of $15.87 billion, and adjusted earnings of 87 cents per share beat the consensus of 72 cents.
    • Raised Guidance — 2026 sales guidance raised to $62 billion to $64 billion from $60.5 billion to $62.5 billion, versus consensus of $62.17 billion; adjusted EPS guidance raised to $2.95 to $3.05 per share from $2.80 to $3.00 per share, versus consensus of $2.96.
    • Growth Drivers — Launched and acquired products contributed $3.8 billion in revenues, and Vyndaqel family sales rose 12% to $1.77 billion; Nurtec and Lorbrena were cited among brands whose higher revenues largely offset lower COVID-19 and Prevnar revenues.
    • COVID and Prevnar Declines — Paxlovid sales fell 63% to $449 million, Comirnaty revenues were $808 million, down 29%, and Prevnar family sales fell 10% to $1.56 billion.
    All 10 details
    • Q3 revenue $16.58 billion beat consensus of $15.87 billion
    • Adjusted earnings 87 cents per share, beating the consensus of 72 cents
    • Launched and acquired products contributed $3.8 billion in revenues
    • Vyndaqel family sales rose 12% to $1.77 billion
    • Paxlovid sales fell 63% to $449 million
    • Comirnaty revenues were $808 million, down 29%
    • Prevnar family sales fell 10% to $1.56 billion
    • 2026 sales guidance raised to $62 billion to $64 billion, from $60.5 billion to $62.5 billion, versus consensus of $62.17 billion
    • 2026 adjusted EPS guidance raised to $2.95 to $3.05 per share, from $2.80 to $3.00 per share, versus consensus of $2.96
    • Nurtec and Lorbrena cited among brands whose higher revenues largely offset lower revenues from COVID-19 products and the Prevnar family

Key Events · Earnings and Guidance · PFE

  • Q3 Revenue Flat, Non-COVID Up 7%

    Third-quarter 2026 revenues were $16.6 billion, down $71 million year-over-year, but excluding Comirnaty and Paxlovid revenue grew 7% operationally and launched and acquired products grew 32%.

  • Guidance Raised on Strong Year-to-Date

    Full-year 2026 revenue guidance rose $1.5 billion at the midpoint to $62.0-$64.0 billion from $60.5-$62.5 billion, and adjusted diluted EPS guidance rose to $2.95-$3.05 from $2.80-$3.00.

  • Adjusted EPS Holds at $0.87

    Reported diluted EPS fell to $0.56 from $0.62, while adjusted diluted EPS was flat at $0.87; nine-month reported net income fell 40% to $5.68 billion on $4.325 billion of asset impairments.

  • New CFO Effective November 1

    Cecile Guegan was appointed Chief Financial Officer and Executive Vice President effective November 1, 2026, and spoke on the quarter.


Analysis · PFE · Life Sciences

The headline top line looks flat, but the mix underneath is far stronger: excluding COVID products, revenue grew 7% operationally, and the launched and acquired portfolio grew 32%. That gave management room to lift full-year revenue guidance by $1.5 billion at the midpoint and raise the adjusted EPS floor by $0.15. Nine-month impairments of $4.3 billion, mostly the $3.8 billion sigvotatug vedotin write-off, explain why reported EPS fell to $0.56 from $0.62 while adjusted EPS held at $0.87. A new CFO, Cecile Guegan, took over November 1, and the company confirmed no buybacks in 2026 with $3.3 billion still authorized — capital is going to the dividend and de-levering instead.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PFE was trading at $30.62 on NYSE in the Life Sciences sector, with a market capitalization of approximately $174.8B. The 52-week trading range was $23.62 to $31.04. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PFE - Latest Insights

PFE
Nov 18, 2026, 7:20 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $28.28
Real-time Price: $28.32 info
Change: +$0.040 (+0.14%) info
Market Cap: $161.391B info
PFE
Nov 16, 2026, 6:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $29.12
Real-time Price: $28.32 info
Change: -$0.800 (-3%) info
Market Cap: $161.391B info
PFE
Nov 13, 2026, 3:19 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $28.85
Real-time Price: $28.32 info
Change: -$0.5325 (-2%) info
Market Cap: $161.391B info
PFE
Nov 11, 2026, 4:30 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $29.45
Real-time Price: $28.32 info
Change: -$1.13 (-4%) info
Market Cap: $161.391B info
PFE
Nov 03, 2026, 8:19 AM EST
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $30.66
Real-time Price: $28.32 info
Change: -$2.34 (-8%) info
Market Cap: $161.391B info